fashion -WSS

fashion

author：focus 2025-10-02 04:36:57 - browse：8215

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： 15 die by electrocution after transformer explodes in northern India

WSS

Senate bill would ban some hospital facility fees

'A game

Covid’s new normal has set in amid another rise in cases

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Flagship, Pfizer team up in deal worth up to $7 billion

'A game

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Jerome Adams on the need for new antivirals for Covid

'A game

How to save PrEP access — and even expand it

Why you get paid to donate plasma but not blood

Bright Health sells Medicare Advantage business to Molina

Assistant physicians can help address the primary care shortage

Dobbs anniversary: the lost opportunity of abortion as health care

Eli Lilly CEO gives to Mike Pence presidential super PAC

Trump demands the U.S. pay no more for drugs than other countries … again

Midwives could help bridge maternal health disparities in the U.S.

hotspot

House passes resolution saying Israel isn't a 'racist or apartheid state'

Lack of darker skin in textbooks, journals harms patients of color

ER docs worry over extreme heat as a 'mass casualty event'

What happened to the House vote on health price transparency?

Eli Lilly CEO gives to Mike Pence presidential super PAC

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Wikipedia

Wikipedia

explore

focus